CDK19 and colorectal carcinoma: Although inhibiting CDK8/CDK19 only has cytostatic effects on CRC cells, a combination of CDK8/CDK19 inhibitors with pharmacological inhibitors of glycolysis might represent a promising avenue for the treatment of highly glycolytic tumors.